Emcure Pharmaceuticals Shares Locked In Upper Circuit Post Q4 Profit Jump, Margin Growth

Emcure Pharmaceuticals Ltd.'s share price soared to hit upper circuit on Friday after its net profit jumped in the fourth quarter of fiscal 2025.

The pharma company reported a 64% surge in net profit to Rs 189 crore in the quarter ended March 31, 2025. This compares to Rs 115.16 crore profit reported in the same quarter last year.

Revenue also increased to Rs 2,116 crore from Rs 1,771 crore in the year ago period.

Margins expanded to 19% from 17.53%. Additionally the company announced a dividend of Rs 3 per share.

Emcure has also recommended a final dividend of Rs 3 per share, subject to approval of the Members of the company at the ensuing Annual General Meeting.

Moreover, the company informed the exchanges on Thursday that its board of directors has approved the incorporation of a wholly-owned subsidiary, called Emcure Generics Pvt. in Pune, Maharashtra, India through a filing.

The share price rose as much as 9.99% to Rs 1,284 apiece, the highest level since Feb. 7, 2025. The stock was locked in upper circuit as of 12:30 p.m. This compares to a 1.02% advance in the NSE Nifty 50.

It has fallen 11.24% on a year-to-date basis. Total traded volume so far in the day stood at 4.6 times its 30-day average. The relative strength index was at 69.21.

Out of three analysts tracking the company, two maintain a 'buy' rating and one recommends 'hold', according to Bloomberg data. The average 12-month consensus price target implies an upside of 13.5%.